Davita (DVA) Stock
Major dialysis provider treating chronic kidney disease patients. Here's the price, business snapshot, and what's worth knowing about Davita in October 2026.
DaVita HealthCare Partners Inc. (DVA) operates a large network of outpatient dialysis centres and offers related clinical services for people with chronic kidney disease and end-stage renal disease. Revenue is driven by patient volumes, payer mix (Medicare, Medicaid and commercial insurers), contractual rates and site utilisation. The business is capital- and labour-intensive and is sensitive to reimbursement policy, regulatory oversight, staffing and negotiated contracts with health plans. Tailwinds include an ageing population and rising chronic disease prevalence, while risks include changes to reimbursement, regulatory enforcement and operational execution. The company’s roughly $9.2bn market capitalisation places it among mid-cap healthcare services names where partnerships and M&A can change the outlook. For investors, focus on patient volumes, payer mix, operating margins, cash flow and regulatory developments. This is general educational information and not personalised investment advice — consider suitability and consult a qualified financial adviser before making decisions.
Davita (DVA) Stock Forecast
Analyst price target, next 12 months
$172.92
-5.8% vs today's $183.64
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Davita have a consensus 12-month target of $172.92, below the current price of $183.64.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 25 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying DaVita's stock as it has potential for growth despite lower target price.
Financial Health
DaVita Inc. is performing well financially, showing strong revenue and cash flow generation capabilities.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Patient Demand Trends
Ageing populations and rising chronic kidney disease rates support long-term demand, though patient volumes and reimbursement can fluctuate.
Payer Mix Impact
Revenue and margins depend heavily on Medicare/Medicaid versus commercial contracts; regulatory or payment changes can materially affect results.
Operational Efficiency Levers
Margins hinge on site utilisation, staffing and cost control; efficiency gains may help profitability but execution risk remains.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
